Evidence map›Paper›PMID 30905846›Full record

ArticleEBioMedicine2019

SUMOylation promotes survival and integration of neural stem cell grafts in ischemic stroke.

Joshua D Bernstock, Luca Peruzzotti-Jametti, Tommaso Leonardi, Nunzio Vicario, Daniel Ye, Yang-Ja Lee, Dragan Maric, Kory R Johnson, Yongshan Mou, Aletta Van Den Bosch and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Enabling Survival of Transplanted Neural Precursor Cells in the Ischemic Brain.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  18. Article
  19. SUMOtherapeutics for Ischemic Stroke.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Joshua D BernstockStroke Branch, National Institutes of Health (NINDS/NIH), National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA; Department of Clinical Neurosciences, University of Cambridge, UK. Electronic address: bernstockjd@ninds.nih.gov.
Luca Peruzzotti-JamettiDepartment of Clinical Neurosciences, University of Cambridge, UK; NIHR Biomedical Research Centre, University of Cambridge, UK. Electronic address: lp429@cam.ac.uk.
Tommaso LeonardiDepartment of Clinical Neurosciences, University of Cambridge, UK; NIHR Biomedical Research Centre, University of Cambridge, UK.
Nunzio VicarioDepartment of Clinical Neurosciences, University of Cambridge, UK; Department of Biomedical and Biotechnological Sciences, Physiology Section, University of Catania, Italy.
Daniel YeStroke Branch, National Institutes of Health (NINDS/NIH), National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
Yang-Ja LeeStroke Branch, National Institutes of Health (NINDS/NIH), National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
Dragan MaricFlow and Imaging Cytometry Core Facility, National Institutes of Health (NINDS/NIH), National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
Kory R JohnsonBioinformatics Section, Information Technology & Bioinformatics Program, Division of Intramural Research (DIR), (NINDS/NIH), Bethesda, MD, USA.
Yongshan MouStroke Branch, National Institutes of Health (NINDS/NIH), National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
Aletta Van Den BoschDepartment of Clinical Neurosciences, University of Cambridge, UK.
Mark WinterboneDepartment of Clinical Neurosciences, University of Cambridge, UK.
Gregory K FriedmanDepartment of Pediatrics and Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Robin J M FranklinDepartment of Clinical Neurosciences, University of Cambridge, UK; Wellcome Trust-Medical Research Council Stem Cell Institute, University of Cambridge, UK.
John M HallenbeckStroke Branch, National Institutes of Health (NINDS/NIH), National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA. Electronic address: hallenbj@ninds.nih.gov.
Stefano PluchinoDepartment of Clinical Neurosciences, University of Cambridge, UK; NIHR Biomedical Research Centre, University of Cambridge, UK. Electronic address: spp24@cam.ac.uk.
National Institutes of Health · USUniversity of Cambridge · GBOffice of Extramural Research · USUniversity of Alabama at Birmingham · USWellcome/MRC Cambridge Stem Cell Institute · GB

Funding

Medical Research Council G0300336Medical Research Council G0300338Medical Research Council G0700392Medical Research Council G0701476Medical Research Council G0802545Medical Research Council MC_PC_12009Medical Research Council MR/K008803/1Medical Research Council MR/M010503/1Wellcome Trust
6 · The paper itself

Abstract

backgroundNeural stem cell (NSC)-based therapies hold great promise for treating diseases of the central nervous system (CNS). However, several fundamental problems still need to be overcome to fully exploit the clinical potential of NSC therapeutics. Chief among them is the limited survival of NSC grafts within hostile microenvironments.

methodsHerein, we sought to engineer NSCs in an effort to increase graft survival within ischemic brain lesions via upregulation of global SUMOylation, a post-translational modification critically involved in mediating tolerance to ischemia/reperfusion.

findingsNSCs overexpressing the SUMO E2-conjugase Ubc9 displayed resistance to oxygen-glucose-deprivation/restoration of oxygen/glucose (OGD/ROG) and enhanced neuronal differentiation in vitro, as well as increased survival and neuronal differentiation when transplanted in mice with transient middle cerebral artery occlusion in vivo.

interpretationOur work highlights a critical role for SUMOylation in NSC biology and identifies a biological pathway that can be targeted to increase the effectiveness of exogenous stem cell medicines in ischemic stroke. FUND: Intramural Research Program of the NINDS/NIH, the Italian Multiple Sclerosis Foundation (FISM), the Bascule Charitable Trust, NIH-IRTA-OxCam and Wellcome Trust Research Training Fellowships.

Indexed as

Cell SurvivalAnimalsBiomarkersCell CycleComputational BiologyEnergy MetabolismGene ExpressionGene Expression ProfilingGlucoseMaleMiceMice, TransgenicNeural Stem CellsNeurogenesisNeuronsOxygenBiomarkersGlucoseOxygenUbiquitin-Conjugating EnzymesUbiquitin-Conjugating Enzyme UBC9Cell therapyCellular engineeringIschemia/reperfusionNeural stem cells (NSCs)Regenerative medicineStrokeSUMOylationUbc9

Identifiers

PMID30905846
PMCPMC6491415
OpenAlexW2925210893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.